KAPUALabs - Nova (Page 164)

An institutional analysis of Meta's forced exit from VR, massive layoffs, and aggressive AI infrastructure buildout.

By KAPUALabs

/ 19 Jun 2026

While retail flees, insiders and institutions see a 18x P/E and a strong buy consensus as too compelling to ignore.

By KAPUALabs

/ 19 Jun 2026

How Instagram Plus, Facebook Plus, and WhatsApp Plus reshape Meta's revenue model and competitive moat.

By KAPUALabs

/ 19 Jun 2026

Alleged scheme exploited PBM rebates through secondary-market sales, exposing material financial exposure for Lilly's top-selling drug.

By KAPUALabs

/ 19 Jun 2026

An in-depth look at Meta's strategic pivot from 8,000 layoffs to a $20 billion subscription bet and massive AI investments.

By KAPUALabs

/ 19 Jun 2026

From 1 billion Meta AI users to automated code reviews, artificial intelligence is rewriting Meta's growth story and competitive moat.

By KAPUALabs

/ 19 Jun 2026

A comprehensive analysis of Meta's Q1 2026 beat, AI-driven margin expansion, and the valuation paradox underlying robust fundamentals.

By KAPUALabs

/ 19 Jun 2026

As hyperscalers race for compute sovereignty, Meta faces unique regulatory and geopolitical hurdles.

By KAPUALabs

/ 19 Jun 2026

How HBM shortages, a 42% VR slump, and ad shifts reshape Meta's path to 2030.

By KAPUALabs

/ 18 Jun 2026

An in-depth analysis of how Eli Lilly is de-risking its supply chain through US capacity expansion and advanced therapeutic delivery platforms.

By KAPUALabs

/ 18 Jun 2026

With a quick ratio of 2.35, low leverage, and a divided analyst crowd, Meta navigates layoffs and AI ambitions.

By KAPUALabs

/ 18 Jun 2026

A deep dive into Meta's strategy to monetize WhatsApp through subscriptions and AI, facing EU regulatory challenges and security threats.

By KAPUALabs

/ 18 Jun 2026